Brentuximab Vedotin + Nivolumab for Hodgkin's Lymphoma
Trial Summary
What is the purpose of this trial?
This phase II trial investigates how well brentuximab vedotin and nivolumab work in treating patients with classical Hodgkin lymphoma that has come back after initial treatment (relapsed) or has not responded to initial treatment (refractory). Brentuximab vedotin is a monoclonal antibody, brentuximab, linked to a toxic agent called vedotin. Brentuximab attaches to CD30 positive cancer cells in a targeted way and delivers vedotin to kill them. Nivolumab is an antibody that enhances the immune system to better fight Hodgkin lymphoma cells. Giving brentuximab vedotin and nivolumab may be able to defer stem cell transplant treatment and spare the considerable cost and toxicity on transplantation.
Will I have to stop taking my current medications?
The trial protocol does not specify if you need to stop taking your current medications. However, you cannot take certain investigational therapies or systemic treatments like high-dose corticosteroids within 14 days of starting the study drugs. It's best to discuss your specific medications with the study team.
What data supports the effectiveness of the drug combination Brentuximab Vedotin and Nivolumab for treating Hodgkin's Lymphoma?
Research shows that Brentuximab Vedotin, when used alone or in combination with other drugs, has been effective in treating Hodgkin's Lymphoma, especially in patients who have relapsed after previous treatments. It has shown high response rates and prolonged survival in various trials, making it a promising option for those with difficult-to-treat cases.12345
Is the combination of Brentuximab Vedotin and Nivolumab safe for humans?
Brentuximab Vedotin is generally well tolerated, with common side effects like peripheral neuropathy (nerve damage causing tingling or numbness) and neutropenia (low white blood cell count). Nivolumab, an anti-PD1 immunotherapy, can cause immune-related side effects that are varied and unpredictable, such as skin rash and lung issues.25678
How is the drug combination of Brentuximab Vedotin and Nivolumab unique for treating Hodgkin's Lymphoma?
This drug combination is unique because it combines Brentuximab Vedotin, an antibody-drug that targets a specific protein on cancer cells, with Nivolumab, which helps the immune system attack cancer cells. This approach is particularly useful for patients who have not responded to other treatments or are not suitable for standard chemotherapy.1491011
Research Team
Alex F. Herrera
Principal Investigator
City of Hope Medical Center
Eligibility Criteria
This trial is for adults with classical Hodgkin lymphoma that has returned or didn't respond to first treatment. They must have had only one prior therapy, no severe allergies to the drugs being tested, and no active major diseases like heart problems or uncontrolled infections. Participants need normal organ function tests and agree to use birth control.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive brentuximab vedotin and nivolumab intravenously every 21 days for up to 16 cycles
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Brentuximab Vedotin
- Nivolumab
Brentuximab Vedotin is already approved in United States, European Union for the following indications:
- Hodgkin lymphoma
- Systemic anaplastic large cell lymphoma
- Primary cutaneous anaplastic large cell lymphoma
- CD30-expressing mycosis fungoides
- Peripheral T-cell lymphoma
- Hodgkin lymphoma
- Systemic anaplastic large cell lymphoma
- Cutaneous T-cell lymphoma
Find a Clinic Near You
Who Is Running the Clinical Trial?
City of Hope Medical Center
Lead Sponsor
National Cancer Institute (NCI)
Collaborator